Abstract
Meeting abstracts Antibody-interferon-alpha (IFNα) fusion proteins represent a cancer therapeutic with properties of an antibody-drug conjugate and an immunotherapy, having both direct anti-tumor and immune-activating effects. We report the anti-tumor activity of IGN004, an antibody-IFNα fusion
Highlights
Antibody-interferon-alpha (IFNa) fusion proteins represent a cancer therapeutic with properties of an antibodydrug conjugate and an immunotherapy, having both direct anti-tumor and immune-activating effects
IGN004 unfused antibody bound to the majority of tumor cell lines and primary tumors assessed
In an in vitro T cell killing assay using TALL-104 cells as effectors and A549 nonsmall cell lung cancer (NSCLC) cells as targets, the addition of IGN004 led to enhanced effector cell killing of tumor (69.2% killing without IGN004 vs. 100% killing with IGN004; p = 0.001)
Summary
Antibody-interferon-alpha (IFNa) fusion proteins represent a cancer therapeutic with properties of an antibodydrug conjugate and an immunotherapy, having both direct anti-tumor and immune-activating effects. We report the anti-tumor activity of IGN004, an antibody-IFNa fusion protein against a novel tumor-associated antigen expressed by many solid and liquid tumors
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
